Clinical Trials
78 trialsPICC-3
Sun Yat-sen University
LIGHT
Sun Yat-sen University
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
IPROC
Canadian Cancer Trials Group
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
Sun Yat-sen University
TRIPLE-PATH
Jinling Hospital, China
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Sun Yat-sen University
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
FACT-TN
Sun Yat-sen University
2025-370
Henan Cancer Hospital
WOLF
University of Pittsburgh
TORCH-iTNT
Fudan University
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd.
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Shanghai Chest Hospital
NEOTRIO-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Sun Yat-sen University
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Stanford University
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
University of Chicago
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
First Affiliated Hospital of Zhejiang University
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Tang-Du Hospital
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
First Affiliated Hospital of Zhejiang University
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
Sun Yat-sen University
PICC
Sun Yat-sen University
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
RemeGen Co., Ltd.
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
Elpiscience Biopharma, Ltd.
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Emory University
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
LaNova Medicines Limited
Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
Shanghai Chest Hospital
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
First Affiliated Hospital of Zhejiang University
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy
Guangdong Provincial People's Hospital
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
Xijing Hospital
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
Xinqiao Hospital of Chongqing
Toripalimab With Chemotherapy for Sinus Cancer
Dana-Farber Cancer Institute
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
NeoHunter
Second Affiliated Hospital, School of Medicine, Zhejiang University
TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer
Sun Yat-sen University
A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd.
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Sun Yat-sen University
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
Fudan University
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
RemeGen Co., Ltd.
PNACGEC
Shenzhen People's Hospital
RC48&J for EPD
Fujian Medical University Union Hospital